查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405747

美国前列腺癌症医学诊断市场规模、份额、趋势分析报告：按产品类型、PET 产品和细分市场预测，2023-2030 年

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Size, Share & Trends Analysis Report By Type (SPECT, PET), By PET Product (F-18, SR-82/RB-82), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国前列腺癌症医学诊断市场的成长和趋势：

Grand View Research最新报告显示，到2030年，美国前列腺癌核医诊断市场规模预计将达到1.5397亿美元。

2023年至2030年的复合年增长率预计为9.2%。据美国癌症协会（ACS）称，2019年美国将有174,650例前列腺癌新发病例和31,620例前列腺癌死亡病例。

用于改善目标疾病检测的新型放射性药物的市场开拓预计将加速市场成长。例如，正在使用 68Ga 和 18F 放射性同位素开发针对前列腺特异性膜抗原 (PSMA) 的新型显影剂。此外，研究人员进行了大量研究，以开发用于正子断层扫描 (PET) 的新型诊断剂，与现有试剂相比，其效率更高。例如，89Zr-huJ591 是一种用于 PET 检测前列腺癌的显影剂。该药物正处于 I/II阶段临床试验，很可能在预测期内上市。

对准确诊断方法的需求不断增长预计将推动美国前列腺癌症核医学诊断市场的成长。 PET 通常与 MRI 和电脑断层扫描相结合，以提高恶性的诊断准确性。因此，研究人员正在研究 PET/MRI 以改善患者的治疗结果。例如，2018年12月，《核子医学杂誌》发表的一项研究表明，68Ga-PSMA-11 PET/MRI在检测目标肿瘤方面具有优势。

各种非营利组织资助研究，帮助引入新的肿瘤诊断显像剂。前列腺癌基金会是领先组织之一，20 多年来一直资助各种 PSMA-PET 影像开发研究。此类资助机构和计划的存在预计将在预测期内促进市场成长。

主要市场参与者正在采取策略性措施来加强其在市场上的影响力。例如，2018年2月，Axumin（氟昔洛韦F18）注射液被纳入NCCN（美国综合癌症网络）前列腺癌肿瘤学临床实务指引。临床医生和医疗保健提供者使用的更新指南现在指出，在復发或晚期前列腺癌患者的临床检查中应考虑注射氟西洛素 F18 进行 PET/MRI 或 PET/CT。

美国前列腺癌核医学诊断市场报告亮点：

  • 2022 年，PET 由于在分子层面上提高了生化和生理过程的灵敏度和量化，推动了美国前列腺癌症核医学诊断市场。
  • SR-82/RB-82 领域预计在预测期内复合年增长率为 9.9%。
  • Fluorine-18 将在 2022 年引领 PET 产品，具有更高的诊断效能、更高品质的影像和更短的撷取时间。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国前列腺癌症核医诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 美国前列腺癌症医学诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国前列腺癌症核医诊断市场：类型估计与趋势分析

  • 美国前列腺癌症核医学诊断市场：要点
  • 美国前列腺癌症核医学诊断市场：2022 年和 2030 年类型变化和市场占有率分析
  • SPECT
  • PET

第五章美国前列腺癌症医学诊断市场：PET产品预估及趋势分析

  • 美国前列腺癌症核医学诊断市场：要点
  • 美国前列腺癌症核医学诊断市场：2022年和2030年PET产品趋势和市场占有率分析
  • F-18
  • SR-82/RB-82
  • 其他的

第六章竞争形势

  • 主要参与者的最新进展和影响分析
  • 公司/竞争分类
    • Blue Earth Diagnostics
    • Siemens Healthcare Private Limited
    • Cardinal Health
    • CURIUM PHARMA
    • Lantheus
    • Jubilant Draximage Radiopharmacies, Inc.
    • NCM-USA LLC
    • Telix Pharmaceuticals Limited
    • ARICEUM THERAPEUTICS
    • Novartis AG
    • Life Molecular Imaging
Product Code: GVR-3-68038-584-7

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Growth & Trends:

The U.S. prostate cancer nuclear medicine diagnostics market size is expected to reach USD 153.97 million by 2030, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 9.2% from 2023 to 2030. According to the American Cancer Society (ACS), in 2019, 174,650 new cases and 31,620 deaths caused by caused by prostate cancer are expected to be recorded in U.S. Such high prevalence of the disease is expected to drive the market growth.

Development of novel radiopharmaceuticals to improve the detection of the target disease is anticipated to accelerate the market growth. For instance, new imaging agents targeting Prostate-specific Membrane Antigen (PSMA) are being developed using 68Ga and 18F radioisotopes. In addition, numerous studies are being performed by researchers to develop new diagnostic agents for Positron Emission Tomography (PET) with higher efficiency as compared to the existing agents. For instance, 89Zr-huJ591 is an imaging agent used with PET for the detection of prostate cancer. This agent is in phase I/II of clinical trials, and is likely to get launched over the forecast period.

Growing demand for accurate diagnostic methods is estimated to fuel growth of the U.S. prostate cancer nuclear medicine diagnostics market. PET is commonly integrated with MRI and CT scan to enhance accuracy of diagnosis in malignancies. Therefore, researchers are conducting studies on PET/MRI to improve patient outcomes. For instance, in December 2018, a study was published in The Journal of Nuclear Medicine stating that 68Ga-PSMA-11 PET/MRI can be advantageous in detecting the target tumor.

Various non-profit organizations fund research studies to help introduce new imaging agents for the diagnosis of tumors. The Prostate Cancer Foundation is one of the major organizations that has been funding different studies for the development of PSMA-PET imaging for over 20 years. Presence of such funding organizations and programs is expected to boost the market growth during the forecast period.

Key market players have undertaken strategic initiatives to strengthen their market presence. For instance, in February 2018, Axumin (fluciclovine F 18) injection was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Prostate Cancer. The updated guidelines used by clinicians and healthcare providers stated that fluciclovine F 18 for PET/MRI or PET/CT is considered in the clinical workup of patients with recurrent or advanced prostate cancer.

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Report Highlights:

  • In 2022, PET led the U.S. prostate cancer nuclear medicine diagnostics market owing to increased sensitivity and quantification of biochemical and physiological processes at a molecular level
  • The SR-82/RB-82 segment is expected to expand at a CAGR of 9.9% over the forecast period
  • Fluorine-18 led the PET products in 2022 owing to higher diagnostic performance and high-quality images, with a shorter acquisition time

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. PET product
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type
    • 2.2.2. PET product
  • 2.3. Competitive Insights

Chapter 3. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Key Takeaways
  • 4.2. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. SPECT
    • 4.3.1. SPECT market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. PET
    • 4.4.1. PET market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: PET Product Estimates & Trend Analysis

  • 5.1. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Key Takeaways
  • 5.2. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: PET Product Movement & Market Share Analysis, 2022 & 2030
  • 5.3. F-18
    • 5.3.1. F-18 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. SR-82/RB-82
    • 5.4.1. SR-82/RB-82 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Participants
  • 6.2. Company/Competition Categorization
    • 6.2.1. Blue Earth Diagnostics
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Siemens Healthcare Private Limited
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Cardinal Health
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. CURIUM PHARMA
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Lantheus
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Jubilant Draximage Radiopharmacies, Inc.
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. NCM-USA LLC
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. Telix Pharmaceuticals Limited
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. ARICEUM THERAPEUTICS
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Novartis AG
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. Life Molecular Imaging
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. prostate cancer nuclear medicine diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. prostate cancer nuclear medicine diagnostics market, by PET product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 U.S. prostate cancer nuclear medicine diagnostics: market outlook
  • Fig. 8 U.S. prostate cancer nuclear medicine diagnostics market: competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 U.S. prostate cancer nuclear medicine diagnostics market driver impact
  • Fig. 13 U.S. prostate cancer nuclear medicine diagnostics market restraint impact
  • Fig. 14 U.S. prostate cancer nuclear medicine diagnostics market strategic initiatives analysis
  • Fig. 15 U.S. prostate cancer nuclear medicine diagnostics market: Type movement analysis
  • Fig. 16 U.S. prostate cancer nuclear medicine diagnostics market: Type outlook and key takeaways
  • Fig. 17 SPECT market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 PET market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. prostate cancer nuclear medicine diagnostics market: PET product movement analysis
  • Fig. 20 U.S. prostate cancer nuclear medicine diagnostics market: PET product outlook and key takeaways
  • Fig. 21 F-18 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 SR-82/RB-82 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)